{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:50:27Z","timestamp":1778575827620,"version":"3.51.4"},"reference-count":206,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Institute of Nanoscience and Nanotechnology","award":["IN2UB ART2018"],"award-info":[{"award-number":["IN2UB ART2018"]}]},{"DOI":"10.13039\/501100001871","name":"Portuguese Science and Technology Foundation","doi-asserted-by":"publisher","award":["M-ERA-NET\/0004\/2015 (PAIRED)"],"award-info":[{"award-number":["M-ERA-NET\/0004\/2015 (PAIRED)"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The eye presents extensive perspectives and challenges for drug delivery, mainly because of the extraordinary capacity, intrinsic to this path, for drugs to permeate into the main circulatory system and also for the restrictions of the ocular barriers. Depending on the target segment of the eye, anterior or posterior, the specifications are different. The ocular route experienced in the last decades a lot of progresses related with the development of new drugs, improved formulations, specific-designed delivery and even new routes to administer a drug. Concomitantly, new categories of materials were developed and adapted to encapsulate drugs. With such advances, a multiplicity of parameters became possible to be optimized as the increase in bioavailability and decreased toxic effects of medicines. Also, the formulations were capable to easily adhere to specific tissues, increase the duration of the therapeutic effect and even target the delivery of the treatment. The ascending of new delivery systems for ocular targeting is a current focus, mainly because of the capacity to extend the normal time during which the drug exerts its therapeutic effect and, so, supplying the patients with a product which gives them fewer side effects, fewer number of applications and even more effective outcomes to their pathologies, surpassing the traditionally-used eye drops. Depending on the systems, some are capable of increasing the duration of the drug action as gels, emulsions, prodrugs, liposomes, and ocular inserts with hydrophilic properties, improving the absorption by the cornea. In parallel, other devices use as a strategy the capacity to sustain the release of the carried drugs by means of erodible and non-erodible matrices. This review discusses the different types of advanced formulations used for ocular delivery of therapeutics presenting the most recent patents according to the clinical applications.<\/jats:p>","DOI":"10.3390\/pharmaceutics11090460","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T03:14:41Z","timestamp":1567998881000},"page":"460","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":174,"title":["Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents"],"prefix":"10.3390","volume":"11","author":[{"given":"Eliana B.","family":"Souto","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, 3000-458 Coimbra, Portugal"},{"name":"CEB\u2014Centre of Biological Engineering, University of Minho, Campus de Gualtar 4710-057 Braga, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8502-8701","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Dias-Ferreira","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, 3000-458 Coimbra, Portugal"}]},{"given":"Ana","family":"L\u00f3pez-Machado","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain"}]},{"given":"Miren","family":"Ettcheto","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED), University of Barcelona, 08028 Barcelona, Spain"},{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain"}]},{"given":"Amanda","family":"Cano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED), University of Barcelona, 08028 Barcelona, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1229-5956","authenticated-orcid":false,"given":"Antonio","family":"Camins Espuny","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED), University of Barcelona, 08028 Barcelona, Spain"},{"name":"Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1269-3847","authenticated-orcid":false,"given":"Marta","family":"Espina","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain"}]},{"given":"Maria Luisa","family":"Garcia","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED), University of Barcelona, 08028 Barcelona, Spain"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2571-108X","authenticated-orcid":false,"given":"Elena","family":"S\u00e1nchez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, 3000-458 Coimbra, Portugal"},{"name":"Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain"},{"name":"Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, 08028 Barcelona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Neurodegenerativas (CIBERNED), University of Barcelona, 08028 Barcelona, Spain"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1442-9071.2010.02363.x","article-title":"Anatomy and physiology of the human eye: Effects of mucopolysaccharidoses disease on structure and function\u2014A review","volume":"38","author":"Willoughby","year":"2010","journal-title":"Clin. Exp. Ophthalmol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Mitra, A.K. (2013). 1\u2014Eye: Anatomy, physiology and barriers to drug delivery. Ocular Transporters and Receptors, Woodhead Publishing Limited.","DOI":"10.1533\/9781908818317.1"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular Drug Delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1248\/yakushi.16-00089","article-title":"Design of Novel Ophthalmic Formulation Containing Drug Nanoparticles and Its Usefulness as Anti-glaucoma Drugs","volume":"136","author":"Nagai","year":"2016","journal-title":"Yakugaku Zasshi"},{"key":"ref_5","first-page":"121","article-title":"Therapeutic challenges in ocular delivery of lipid based emulsion","volume":"5","author":"Tiwari","year":"2018","journal-title":"Egypt. J. Basic Appl. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.addr.2017.04.001","article-title":"Nanoparticles for drug delivery to the anterior segment of the eye","volume":"122","author":"Janagam","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_7","first-page":"70","article-title":"Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye\u2014Part I - Barriers and determining factors in ocular delivery","volume":"100","author":"Espina","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000455276","article-title":"Drug Delivery to the Posterior Segment of the Eye","volume":"58","author":"Moisseiev","year":"2017","journal-title":"Dev. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/187221107780831923","article-title":"Recent patents and advances in ophthalmic drug delivery","volume":"1","author":"Janoria","year":"2007","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/eye.2013.187","article-title":"Eye drop instillation technique in patients with glaucoma","volume":"27","author":"Tatham","year":"2013","journal-title":"Eye"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.12.009","article-title":"Expression, activity and pharmacokinetic impact of ocular transporters","volume":"126","author":"Hellinen","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/jop.1994.10.69","article-title":"The role of iontophoresis in ocular drug delivery","volume":"10","author":"Sarraf","year":"1994","journal-title":"J. Ocul. Pharm."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1208\/s12249-016-0589-9","article-title":"Potential Use of Cyclodextrin Complexes for Enhanced Stability, Anti-inflammatory Efficacy, and Ocular Bioavailability of Loteprednol Etabonate","volume":"18","author":"Soliman","year":"2017","journal-title":"AAPS Pharm. Sci. Tech."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Abdelkader, H., Fathalla, Z., Moharram, H., Ali, T.F.S., and Pierscionek, B. (2018). Cyclodextrin Enhances Corneal Tolerability and Reduces Ocular Toxicity Caused by Diclofenac. Oxid. Med. Cell. Longev., 13.","DOI":"10.1155\/2018\/5260976"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/polym3010193","article-title":"Recent Advances in Ocular Drug Delivery Systems","volume":"3","author":"Kuno","year":"2011","journal-title":"Polymers"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/eye.2011.82","article-title":"Novel drug delivery systems for glaucoma","volume":"25","author":"Lavik","year":"2011","journal-title":"Eye"},{"key":"ref_17","unstructured":"Belanger, D. (2001). Omega Chain Modified 15-Hydroxyeicosatetraenoic Acid Derivatives and Methods of Their Use for the Treatment of Dry Eye. (US6326499), U.S. Patent."},{"key":"ref_18","unstructured":"Klimko, P.H., Hellberg, M.R., Falck, J.R., and Conrow, R.E. (2003). Hydroxyeicosatetraenoic Acid Analogs and Methods of Their Use in Treating Dry Eye Disorders. (US6552084), U.S. Patent."},{"key":"ref_19","unstructured":"Klagsbrun, M.S., and Soker, S. (2004). Peptide Antagonists of Vascularendothelial Growth Factor. (US6777534), U.S. Patent."},{"key":"ref_20","unstructured":"Haddox, J.P., Pfister, R.R., Blalock, J.E., and Villain, M. (2004). Synthetic Complementary Peptides and Ophthalmologic Uses Thereof. (US6762166), U.S. Patent."},{"key":"ref_21","unstructured":"Old, D.D., and Dinh, D.T. (2005). Piperidinyl Prostaglandin e Analogs. (US20050164990), U.S. Patent."},{"key":"ref_22","unstructured":"Woodward, D.K., Krauss, A.H., Burk, R.M., Holoboski, M., and Posner, M.F. (2005). EP4 Agonists as Agents for Lowering Intraocular Pressure. (US20040102499), U.S. Patent."},{"key":"ref_23","unstructured":"Graff, G.H., Hellberg, M.R., and Yanni, J.M. (2003). Method of Treating Ocular Inflammatory and Angiogenesis-Related Disorders of the Posterior Segment of the Eye Using an Amide Derivative of Flurbiprofen or Ketorolac. (US20020183376), U.S. Patent."},{"key":"ref_24","unstructured":"Spina, J.W., and Weibel, M.K. (1986). Intralenticular Cataract Surgery. (US4078564), U.S. Patent."},{"key":"ref_25","unstructured":"First, E. (2007). Methods and Compositions for Treating Eye Disorders. (US20040234532), U.S. Patent."},{"key":"ref_26","unstructured":"Fleiszig, S.M., and McNamara, N.A. (2006). Use of Lipopolysaccharides to Manage Corneal Infections and Wounds. (US6984622), U.S. Patent."},{"key":"ref_27","unstructured":"Dreyer, E. (2003). Calcium Blockers to Treat Proliferative Vitreoretinopathy. (US20030060510), U.S. Patent."},{"key":"ref_28","unstructured":"Dinh, D. (2008). Prostaglandin Analogs. (US7427614), U.S. Patent."},{"key":"ref_29","unstructured":"Pershadsingh, H. (2000). 1,2-Dithiolane Derivatives. (US6127394), U.S. Patent."},{"key":"ref_30","unstructured":"Borchardt, A.J., Kania, R.S., and Palmer, C.L. (2006). Indazole Compounds and Pharmaceutical Compositions for Inhibiting Protein Kinases, and Methods for Their Use. (US7053107), U.S. Patent."},{"key":"ref_31","first-page":"2","article-title":"Preservatives from the eye drops and the ocular surface","volume":"59","author":"Coroi","year":"2015","journal-title":"Romanian J. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0378-5173(96)04663-7","article-title":"Evaluation of ocular permeation enhancers: In vitro effects on corneal transport of four \u03b2-blockers, and in vitro\/in vivo toxic activity","volume":"142","author":"Saettone","year":"1996","journal-title":"Int. J. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1208\/ps040102","article-title":"Ocular tolerance of absorption enhancers in ophthalmic preparations","volume":"4","author":"Furrer","year":"2002","journal-title":"AAPS Pharm. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4155\/tde.10.40","article-title":"Recent advances in ophthalmic drug delivery","volume":"1","author":"Kompella","year":"2010","journal-title":"Ther. Deliv."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4155\/tde.14.75","article-title":"Advances in ophthalmic drug delivery","volume":"5","author":"Morrison","year":"2014","journal-title":"Ther. Deliv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1002\/jps.10258","article-title":"In vitro evaluation of the permeation enhancing effect of polycarbophil-cysteine conjugates on the cornea of rabbits","volume":"91","author":"Hornof","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3109\/02713683.2011.593728","article-title":"Effect of hydroxypropyl-beta-cyclodextrin on the ocular bioavailability of dexamethasone from a pH-induced mucoadhesive hydrogel","volume":"36","author":"Kesavan","year":"2011","journal-title":"Curr. Eye Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1034\/j.1600-0420.2002.800205.x","article-title":"Cyclodextrins in eye drop formulations: Enhanced topical delivery of corticosteroids to the eye","volume":"80","author":"Loftsson","year":"2002","journal-title":"Acta Ophthalmol. Scand."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0169-409X(95)00012-V","article-title":"Ocular drug delivery conventional ocular formulations","volume":"16","author":"Lang","year":"1995","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: Challenges and novel formulation approaches","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/0192623307310955","article-title":"Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations","volume":"36","author":"Short","year":"2008","journal-title":"Toxicol. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1773-2247(11)50010-3","article-title":"Emulsions and microemulsions for ocular drug delivery","volume":"21","author":"Peng","year":"2011","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejpb.2004.03.033","article-title":"The potential of lipid emulsion for ocular delivery of lipophilic drugs","volume":"58","author":"Tamilvanan","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/OED.S7791","article-title":"Review of Azithromycin Ophthalmic 1% Solution (AzaSite(\u00ae)) for the Treatment of Ocular Infections","volume":"4","author":"Opitz","year":"2012","journal-title":"Ophthalmol. Eye Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/ICO.0b013e3180de1c38","article-title":"An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops","volume":"26","author":"Ousler","year":"2007","journal-title":"Cornea"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3928\/1081597X-20080501-04","article-title":"The effect of cyclosporine A (Restasis) on recovery of visual acuity following LASIK","volume":"24","author":"Ursea","year":"2008","journal-title":"J. Refract. Surg."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Dubald, M., Bourgeois, S., Andrieu, V., and Fessi, H. (2018). Ophthalmic Drug Delivery Systems for Antibiotherapy\u2014A Review. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10010010"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"604204","DOI":"10.1155\/2012\/604204","article-title":"Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion, Novasorb","volume":"2012","author":"Lallemand","year":"2012","journal-title":"J. Drug Deliv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jop.2010.0093","article-title":"Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits","volume":"27","author":"Tajika","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1080\/03639040802680271","article-title":"Lipid emulsions as a potential delivery system for ocular use of azithromycin","volume":"35","author":"Liu","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijpharm.2011.03.041","article-title":"Novel NSAIDs ophthalmic formulation: Flurbiprofen axetil emulsion with low irritancy and improved anti-inflammation effect","volume":"412","author":"Shen","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s13346-015-0262-y","article-title":"Formulation and comparative evaluation of HPMC and water soluble chitosan-based sparfloxacin nanosuspension for ophthalmic delivery","volume":"6","author":"Ambhore","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_53","first-page":"709","article-title":"Solubility of ocular therapeutic agents in self-emulsifying oils. I. Self-emulsifying oils for ocular drug delivery: Solubility of indomethacin, aciclovir and hydrocortisone","volume":"66","author":"Sznitowska","year":"2009","journal-title":"Acta Pol. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000267160","article-title":"A submicron emulsion as ocular vehicle for delta-8-tetrahydrocannabinol: Effect on intraocular pressure in rabbits","volume":"24","author":"Muchtar","year":"1992","journal-title":"Ophthalmic Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0039-6257(78)90178-9","article-title":"Ophthalmic ointments","volume":"22","author":"Robin","year":"1978","journal-title":"Surv. Ophthalmol."},{"key":"ref_56","first-page":"267","article-title":"Route of absorption of drug and ointment after application to the eye","volume":"10","author":"Scruggs","year":"1978","journal-title":"Ann. Ophthalmol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00004397-198002030-00009","article-title":"Aqueous formulations and ointments","volume":"20","author":"MacKeen","year":"1980","journal-title":"Int. Ophthalmol. Clin."},{"key":"ref_58","unstructured":"Polin, R.A., and Ditmar, M.F. (2011). CHAPTER 11\u2014Infectious Diseases. Pediatric Secrets, Mosby. [5th ed.]."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Ye, Z.-K., Li, C., and Zhai, S.-D. (2014). Guidelines for Therapeutic Drug Monitoring of Vancomycin: A Systematic Review. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099044"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Baranowski, P., Karolewicz, B., Gajda, M., and Pluta, J. (2014). Ophthalmic Drug Dosage Forms: Characterisation and Research Methods. Sci. World J., 14.","DOI":"10.1155\/2014\/861904"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/pharmaceutics4020252","article-title":"Breakdown of the blood-ocular barrier as a strategy for the systemic use of nanosystems","volume":"4","author":"Occhiutto","year":"2012","journal-title":"Pharmaceutics"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10156-002-0219-1","article-title":"The intraocular dynamics of vancomycin hydrochloride ophthalmic ointment (TN-011) in rabbits","volume":"9","author":"Fukuda","year":"2003","journal-title":"J. Infect. Chemother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10156-009-0708-6","article-title":"The inhibitory effect of vancomycin ointment on the manifestation of MRSA keratitis in rabbits","volume":"15","author":"Eguchi","year":"2009","journal-title":"J. Infect. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.2174\/1381612823666171122103849","article-title":"Current Challenges and Future of Lipid nanoparticles formulations for topical drug application to oral mucosa, skin, and eye","volume":"23","author":"Guilherme","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bcp.12268","article-title":"Formulations for children: Problems and solutions","volume":"79","author":"Batchelor","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: Review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0939-6411(03)00159-0","article-title":"Evaluation of ophthalmic suspensions using surface tension","volume":"57","author":"Yasueda","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1089\/jam.1994.7.Suppl_1.S-3","article-title":"Pharmaceutical formulations\u2014Suspensions and solutions","volume":"7","author":"Edman","year":"1994","journal-title":"J. Aerosol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s12325-008-0019-9","article-title":"Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension","volume":"25","author":"Scoper","year":"2008","journal-title":"Adv. Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: An overview","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2147\/OPTH.S118409","article-title":"Systemic side effects of eye drops: A pharmacokinetic perspective","volume":"10","author":"Farkouh","year":"2016","journal-title":"Clin. Ophthalmol. (Auckl. N.Z.)"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s13555-012-0012-8","article-title":"A Pilot Study to Investigate the Efficacy of Tobramycin\u2013Dexamethasone Ointment in Promoting Wound Healing","volume":"2","author":"Andrew","year":"2012","journal-title":"Dermatol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/jop.2016.0096","article-title":"Randomized Comparison Between Rebamipide Ophthalmic Suspension and Diquafosol Ophthalmic Solution for Dry Eye After Penetrating Keratoplasty","volume":"33","author":"Kobashi","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1358\/dot.2011.47.6.1549023","article-title":"Nanotechnology in ocular delivery: Current and future directions","volume":"47","author":"Sultana","year":"2011","journal-title":"Drugs Today (Barc)"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/mabi.201100419","article-title":"Nanomaterials for Ocular Drug Delivery","volume":"12","author":"Liu","year":"2012","journal-title":"Macromol. Biosci."},{"key":"ref_76","unstructured":"Ousler, G.W., Chapin, M.J., and Abelson, M.B. (2008). Use of Neurotransmitters and Neuropeptides for the Treatment of Dry Eye Diseases and Related Conditions. (US20080261890), U.S. Patent."},{"key":"ref_77","unstructured":"Gadd, M.G., and Graff, G. (2008). Modulation of Polysialylated Neural Adhesion Molecules (Psa-Ncam) as a Regulator of Ocular Disease. (US20080132451), U.S. Patent."},{"key":"ref_78","unstructured":"Bartels, S.P.L., Lam, T.T., Shafiee, A., and Lin, Y.Q. (2008). Delivery System for Antiangiogenic and Antiinflammatory Pharmaceuticals and Method of Use. (US20080125377), U.S. Patent."},{"key":"ref_79","unstructured":"Alam, A., Reichel, E., and Busbee, B. (2008). Aqueous Gel Formulation and Method for Inducing Topical Anesthesia. (US20080020044 A1), U.S. Patent."},{"key":"ref_80","unstructured":"Furfine, E., Dix, D., Graham, K.S., and Frye, K. (2009). VEGF Antagonist Formulations Suitable for Intravitreal Administration. (US20070293432), U.S. Patent."},{"key":"ref_81","unstructured":"Prausnitz, M., Jiang, N.H., and Edelhauser, H.F. (2011). Method for Drug Delivery to Ocular Tissue Using Microneedle. (US20070260201), U.S. Patent."},{"key":"ref_82","unstructured":"Yamamoto, R., Conston, S., and Sierra, D. (2007). Apparatus and Formulations for Suprachoroidal Drug Delivery. (US20070202186A1), U.S. Patent."},{"key":"ref_83","unstructured":"Bhushan, R., and Gin, J.B. (2010). Prevention and Treatment of Ophthalmic Complications of Diabetes. (US20100069335), U.S. Patent."},{"key":"ref_84","unstructured":"Dor, P., Mudumba, S., Nivaggioli, T., and Weber, D.A. (2006). Formulations for Ocular Treatment. (US20060182771), U.S. Patent."},{"key":"ref_85","unstructured":"Carrasquillo, K., Adamis, A.P., Miller, J.W., and Gragoudas, E.S. (2005). Drug Delivery Systems and Use Thereof. (US20050175708), U.S. Patent."},{"key":"ref_86","unstructured":"Chen, J.Q., and Liu, Y. (2008). Pharmaceutical Compositions and Methods for Treating Immune-Response Associated Diseases of the Surface and the Anterior Segment of the Eye. (US20030212090), U.S. Patent."},{"key":"ref_87","unstructured":"Thornion, S., and Troyer, E. (2006). Treatment for Dry Eye Syndrome. (US20060088600), U.S. Patent."},{"key":"ref_88","unstructured":"Gorsek, W. (2003). Eyesight Enhanced Maintenance Composition. (US6649195), U.S. Patent."},{"key":"ref_89","unstructured":"Abelson, M., Gomes, P.J., and Chapin, M.J. (2005). Novel Topical Ophthalmic Formulations. (US20050239745 A1), U.S. Patent."},{"key":"ref_90","unstructured":"Lin, H., and Sung, K.C. (2003). Ophthalmic Drug Delivery Formulations and Method for Preparing the Same. (US6511660), U.S. Patent."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.3109\/10717544.2016.1138342","article-title":"A review on therapeutic contact lenses for ocular drug delivery","volume":"23","author":"Maulvi","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1773-2247(14)50021-4","article-title":"Review of ophthalmic drug delivery by contact lenses","volume":"24","author":"Hsu","year":"2014","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1021\/acs.biomac.5b01387","article-title":"Preparation and Evaluation of Contact Lenses Embedded with Polycaprolactone-Based Nanoparticles for Ocular Drug Delivery","volume":"17","author":"Nasr","year":"2016","journal-title":"Biomacromolecules"},{"key":"ref_94","first-page":"205","article-title":"Dexamethasone transport and ocular delivery from poly(hydroxyethyl methacrylate) gels","volume":"353","author":"Kim","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/2278-344X.107844","article-title":"pHEMA hydrogels: Devices for ocular drug delivery","volume":"1","author":"Tomar","year":"2012","journal-title":"Int. J. Health Allied Sci."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1016\/j.polymer.2012.08.053","article-title":"Stimuli-responsive microgels for the loading and release of functional compounds: Fundamental concepts and applications","volume":"53","author":"Klinger","year":"2012","journal-title":"Polymer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.biomaterials.2004.04.030","article-title":"Ocular release of timolol from molecularly imprinted soft contact lenses","volume":"26","author":"Hiratani","year":"2005","journal-title":"Biomaterials"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/OPX.0b013e3182639dc8","article-title":"Delivery of ketotifen fumarate by commercial contact lens materials","volume":"89","author":"Soluri","year":"2012","journal-title":"Optom. Vis. Sci."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1186\/1556-276X-9-247","article-title":"Dendrimers: Synthesis, applications, and properties","volume":"9","author":"Abbasi","year":"2014","journal-title":"Nanoscale Res. Lett."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1021\/acs.bioconjchem.5b00031","article-title":"Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges","volume":"26","author":"Wu","year":"2015","journal-title":"Bioconjugate Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/nbt1171","article-title":"Designing dendrimers for biological applications","volume":"23","author":"Lee","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jconrel.2004.09.015","article-title":"Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide","volume":"102","author":"Vandamme","year":"2005","journal-title":"J. Controll. Release"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"732340","DOI":"10.1155\/2013\/732340","article-title":"Dendrimeric Systems and Their Applications in Ocular Drug Delivery","volume":"2013","author":"Yavuz","year":"2013","journal-title":"Sci. World J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.sjopt.2015.10.002","article-title":"Intraocular lens implants: Do they come with a life time guaranty?","volume":"29","author":"Beiko","year":"2015","journal-title":"Saudi J. Ophthalmol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bmj.320.7227.73","article-title":"Intraocular lens implants: Have come a long way, but the advances are not yet available to all","volume":"320","author":"Allan","year":"2000","journal-title":"BMJ"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/2277-9175.150426","article-title":"Design and development of intraocular polymeric implant systems for long-term controlled-release of clindamycin phosphate for toxoplasmic retinochoroiditis","volume":"4","author":"Tamaddon","year":"2015","journal-title":"Adv. Biomed. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/eye.2016.266","article-title":"The evidence informing the surgeon\u2019s selection of intraocular lens on the basis of light transmittance properties","volume":"31","author":"Li","year":"2017","journal-title":"Eye"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s11095-010-0159-x","article-title":"Biodegradable implants for sustained drug release in the eye","volume":"27","author":"Lee","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2014.06.043","article-title":"Ocular delivery of macromolecules","volume":"190","author":"Kim","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/09273948.2011.568661","article-title":"A functional, nonfunctioning Retisert implant","volume":"19","author":"Hebson","year":"2011","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ophtha.2006.02.021","article-title":"Fluocinolone Acetonide Implant (Retisert) for Noninfectious Posterior Uveitis","volume":"113","author":"Jaffe","year":"2006","journal-title":"Ophthalmology"},{"key":"ref_112","first-page":"5852","article-title":"The Retisert Experience","volume":"51","author":"Jancevski","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/11530970-000000000-00000","article-title":"Biodegradable intraocular therapies for retinal disorders: Progress to date","volume":"27","author":"Kuno","year":"2010","journal-title":"Drugs Aging"},{"key":"ref_114","first-page":"191","article-title":"Implantable Posterior Segment Drug Delivery Devices; Novel Alternatives to Currently Available Treatments","volume":"4","year":"2009","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1590\/S0100-879X2000000700008","article-title":"Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant","volume":"33","author":"Muccioli","year":"2000","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1258\/0956462981922098","article-title":"Intravitreal sustained-release ganciclovir implantation to control cytomegalovirus retinitis in AIDS","volume":"9","author":"Dhillon","year":"1998","journal-title":"Int. J. STD AIDS"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/1567201814666170508104254","article-title":"Recent Advancements in Biodegradable Ocular Implants","volume":"15","author":"Mittal","year":"2018","journal-title":"Curr. Drug Deliv."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1701808","DOI":"10.1002\/smll.201701808","article-title":"Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma","volume":"14","author":"Egea","year":"2018","journal-title":"Small"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s13346-015-0240-4","article-title":"A biodegradable ocular implant for long-term suppression of intraocular pressure","volume":"5","author":"Ng","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/jfb6030650","article-title":"Intraocular Implants for the Treatment of Autoimmune Uveitis","volume":"6","author":"Lee","year":"2015","journal-title":"J. Funct. Biomater."},{"key":"ref_121","first-page":"317","article-title":"Sustained Release Intraocular Drug Delivery Devices for Treatment of Uveitis","volume":"6","author":"Haghjou","year":"2011","journal-title":"J. Ophthalmic Vis. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0974-620X.99368","article-title":"Short-term results of intravitreal dexamethasone implant (Ozurdex\u00ae) in treatment of recalcitrant diabetic macular edema: A case series","volume":"5","author":"Rishi","year":"2012","journal-title":"Oman. J. Ophthalmol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-016-3350-x","article-title":"Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex\u00ae) in its treatment","volume":"254","author":"Garweg","year":"2016","journal-title":"Graefe\u2019s Arch. Clin. Exp. Ophthalmol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000336225","article-title":"Intravitreal Dexamethasone Implant in Patients with Persistent Diabetic Macular Edema","volume":"228","author":"Zucchiatti","year":"2012","journal-title":"Ophthalmologica"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/1872211309666150724101227","article-title":"In Situ Gelling Ophthalmic Drug Delivery System: An Overview and Its Applications","volume":"9","author":"Sheshala","year":"2015","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e20126","DOI":"10.17795\/jjnpp-20126","article-title":"In Situ Gelling Systems for Drug Delivery","volume":"9","author":"Kouchak","year":"2014","journal-title":"Jundishapur J. Nat. Pharm. Prod."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1080\/17425247.2018.1517741","article-title":"In situ gelling and mucoadhesive polymers: Why do they need each other?","volume":"15","author":"Wolf","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2008.01.057","article-title":"In situ gelling hydrogels for pharmaceutical and biomedical applications","volume":"355","author":"Storm","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v26.i1.30","article-title":"In Situ Gelling Polymers in Ocular Drug Delivery Systems: A Review","volume":"26","author":"Mundada","year":"2009","journal-title":"Ther. Drug Carr. Syst."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jop.2012.0200","article-title":"Novel Strategies for Anterior Segment Ocular Drug Delivery","volume":"29","author":"Cholkar","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejpb.2016.10.013","article-title":"Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye\u2014Part II\u2014Ocular drug-loaded lipid nanoparticles","volume":"110","author":"Espina","year":"2017","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3109\/03639041003680826","article-title":"PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate","volume":"36","author":"Gao","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/jop.2009.0059","article-title":"Sustained subconjunctival protein delivery using a thermosetting gel delivery system","volume":"26","author":"Rieke","year":"2010","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_134","unstructured":"Heller, J., Schacht, E., and Toncheva, V. (2006). PEG-Polyacetal and PEG-Polyacetal-POE Graft Copolymers and Pharmaceutical Compositions. (US20060235161), U.S. Patent."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1556-276X-8-102","article-title":"Liposome: Classification, preparation, and applications","volume":"8","author":"Akbarzadeh","year":"2013","journal-title":"Nanoscale Res. Lett."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3109\/10717544.2014.943336","article-title":"Liposomes in topical ophthalmic drug delivery: An update","volume":"23","author":"Agarwal","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Mishra, G.P., Bagui, M., Tamboli, V., and Mitra, A.K. (2011). Recent Applications of Liposomes in Ophthalmic Drug Delivery. J. Drug Deliv., 1\u201314.","DOI":"10.1155\/2011\/863734"},{"key":"ref_138","first-page":"123","article-title":"Nanomedicine for glaucoma: Liposomes provide sustained release of latanoprost in the eye","volume":"7","author":"Natarajan","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jsps.2013.07.003","article-title":"Design of liposomal colloidal systems for ocular delivery of ciprofloxacin","volume":"22","author":"Taha","year":"2014","journal-title":"Saudi Pharm. J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3109\/03639040903419640","article-title":"Positively and negatively charged liposomes as carriers for transdermal delivery of sumatriptan: In vitro characterization","volume":"36","author":"Drhimeur","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0168-3659(99)00192-3","article-title":"Acyclovir-containing liposomes for potential ocular delivery: Corneal penetration and absorption","volume":"63","author":"Law","year":"2000","journal-title":"J. Control. Release"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijpharm.2009.01.001","article-title":"Topical use of Coenzyme Q10-loaded liposomes coated with trimethyl chitosan: Tolerance, precorneal retention and anti-cataract effect","volume":"372","author":"Zhang","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1755-3768.2009.01584.x","article-title":"Liposomes as an ocular delivery system of fluconazole: In-vitro studies","volume":"88","author":"Habib","year":"2010","journal-title":"Acta Ophthalmol."},{"key":"ref_144","first-page":"1921","article-title":"Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): In vitro characterization and improved corneal permeation","volume":"8","author":"Dai","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Bulbake, U., Doppalapudi, S., Kommineni, N., and Khan, W. (2017). Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics, 9.","DOI":"10.3390\/pharmaceutics9020012"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clae.2017.07.007","article-title":"Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs and symptoms?","volume":"41","author":"Essa","year":"2018","journal-title":"Cont. Lens. Anterior Eye"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"538","DOI":"10.5301\/EJO.2011.6324","article-title":"Efficacy of 3 different artificial tears for the treatment of dry eye in frequent computer users and\/or contact lens users","volume":"21","author":"Borges","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.ophtha.2004.02.014","article-title":"Verteporfin in Ocular Histoplasmosis Study, G. Photodynamic therapy with verteporfin in ocular histoplasmosis: Uncontrolled, open-label 2-year study","volume":"111","author":"Rosenfeld","year":"2004","journal-title":"Ophthalmology"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1517\/14656566.5.1.195","article-title":"Verteporfin ocular photodynamic therapy","volume":"5","author":"Bakri","year":"2004","journal-title":"Expert. Opin. Pharmacother."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4155\/tde.12.122","article-title":"Nanomicelles: An emerging platform for drug delivery to the eye","volume":"4","author":"Vadlapudi","year":"2013","journal-title":"Ther. Deliv."},{"key":"ref_151","unstructured":"Mitra, A.K., Cholkar, K., and Mandal, A. (2017). Nanomicelles in Diagnosis and Drug Delivery (Chapter 3). Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices, Elsevier."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2174\/1877912311202020082","article-title":"Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery","volume":"2","author":"Cholkar","year":"2012","journal-title":"Recent Pat. Nanomed."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.4.3.1","article-title":"Topical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery","volume":"4","author":"Cholkar","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijpharm.2009.05.028","article-title":"Polyhydroxyethylaspartamide-based micelles for ocular drug delivery","volume":"378","author":"Civiale","year":"2009","journal-title":"Int. J. Pharm."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/jgm.1093","article-title":"Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters","volume":"9","author":"Tong","year":"2007","journal-title":"J. Gene Med."},{"key":"ref_156","first-page":"4","article-title":"Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa\u00ae) for Dry Eye Disease","volume":"36","author":"Gote","year":"2019","journal-title":"Pharm. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-5793(03)01315-2","article-title":"Effective accumulation of polyion complex micelle to experimental choroidal neovascularization in rats","volume":"557","author":"Ideta","year":"2004","journal-title":"FEBS. Lett."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1700455","DOI":"10.1002\/advs.201700455","article-title":"Nanomicelle-Assisted Targeted Ocular Delivery with Enhanced Antiinflammatory Efficacy In Vivo","volume":"5","author":"Weng","year":"2018","journal-title":"Adv. Sci."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1167\/iovs.12-9872","article-title":"Targeted Administration into the Suprachoroidal Space Using a Microneedle for Drug Delivery to the Posterior Segment of the Eye","volume":"53","author":"Patel","year":"2012","journal-title":"Inv. Ophth. Vis. Sci."},{"key":"ref_160","unstructured":"Khan, I., Saeed, K., and Khan, I. (2017). Nanoparticles: Properties, applications and toxicities. Arabian J. Chem."},{"key":"ref_161","first-page":"609","article-title":"Conjugation of cell-penetrating peptides with poly (lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery","volume":"10","author":"Vasconcelos","year":"2015","journal-title":"Int. J. Nanomed."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.colsurfb.2016.04.054","article-title":"PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen\u2014In vitro, ex vivo and in vivo characterization","volume":"145","author":"Egea","year":"2016","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.sjopt.2014.02.009","article-title":"Nanocarriers of nanotechnology in retinal diseases","volume":"28","year":"2014","journal-title":"Saudi J. Ophthalmol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/0975-7406.111824","article-title":"Nanoparticles laden in situ gel for sustained ocular drug delivery","volume":"5","author":"Gupta","year":"2013","journal-title":"J. Pharm. Bioallied. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1021\/mp900279c","article-title":"Mucoadhesive Nanoparticles as Carrier Systems for Prolonged Ocular Delivery of Gatifloxacin\/Prednisolone Bitherapy","volume":"7","author":"Ibrahim","year":"2010","journal-title":"Mol. Pharm."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ijpharm.2012.10.014","article-title":"Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits","volume":"440","author":"Musumeci","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/0974-9233.106384","article-title":"Nanotechnology Approaches for Ocular Drug Delivery","volume":"20","author":"Xu","year":"2013","journal-title":"Middle East. Afr. J. Ophthalmol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fphar.2012.00188","article-title":"Ocular drug delivery: A clue from nanotechnology","volume":"3","author":"Bucolo","year":"2012","journal-title":"Front. Pharmacol."},{"key":"ref_169","first-page":"150","article-title":"Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration","volume":"14","author":"Amrite","year":"2008","journal-title":"Mol. Vis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.apsb.2016.09.001","article-title":"Nanotechnology-based strategies for treatment of ocular disease","volume":"7","author":"Weng","year":"2017","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijpharm.2007.03.011","article-title":"Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs","volume":"340","author":"Kassem","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.nano.2010.07.003","article-title":"Nanosuspension: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B","volume":"7","author":"Das","year":"2011","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/2231-4040.82950","article-title":"Nanosuspension: An approach to enhance solubility of drugs","volume":"2","author":"Patel","year":"2011","journal-title":"J. Adv. Pharm. Tech. Res."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.apsb.2018.07.011","article-title":"Parenteral nanosuspensions: A brief review from solubility enhancement to more novel and specific applications","volume":"8","author":"Ahire","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.15171\/apb.2016.046","article-title":"Comparison of Different Nanosuspensions as Potential Ophthalmic Delivery Systems for Ketotifen Fumarate","volume":"6","author":"Soltani","year":"2016","journal-title":"Adv. Pharm. Bull."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2010.10.007","article-title":"Hydrocortisone nanosuspensions for ophthalmic delivery: A comparative study between microfluidic nanoprecipitation and wet milling","volume":"149","author":"Ali","year":"2011","journal-title":"J. Control. Release"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00000658-199809000-00009","article-title":"Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector","volume":"228","author":"Yoon","year":"1998","journal-title":"Ann. Surg."},{"key":"ref_178","unstructured":"Brandt, C.R., Kalil, R.E., and Agarwala, S. (2000). Replication Competent, a Virulent Herpes Simplex Virus as a Vector for Neural and Ocular Gene Therapy. (US106826), U.S. Patent."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000434698","article-title":"Ocular Gene Therapy","volume":"55","author":"Campbell","year":"2016","journal-title":"Dev. Ophthalmol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/pgmj.2009.174912rep","article-title":"Republished review: Gene therapy for ocular diseases","volume":"87","author":"Liu","year":"2011","journal-title":"Postgrad. Med. J."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/0974-620X.57308","article-title":"Gene therapy in ophthalmology","volume":"2","author":"Uthra","year":"2009","journal-title":"Oman. J. Ophthalmol."},{"key":"ref_182","unstructured":"Hauswirth, W., Campichiaro, P.A., and Berns, K.I. (2008). Raav Vector Compositions and Methods for the Treatment of Choroidal Neovascularization. (NZ535100), NZ Patent."},{"key":"ref_183","unstructured":"Inana, G., and McLaren, M. (2009). Methods and Compositions for Detecting and Treating Retinal Diseases. (US20090144839), U.S. Patent."},{"key":"ref_184","unstructured":"Stout, J.T., and Appukuttan, B. (2006). Lentiviral Vector-Mediated Gene Transfer and Uses Thereof. (US20060062765), U.S. Patent."},{"key":"ref_185","unstructured":"Davidson, B., Jolly, D.J., Sauter, S.L., Stein, C.S., Dubensky, T.W., and Heth, J.A. (2006). Use of Recombinant Gene Delivery Vectors for Treating or Preventing Lysosomal Storage Disorders. (US20030223963), U.S. Patent."},{"key":"ref_186","unstructured":"Manning, W., Dwarki, V.J., Rendahl, K., Zhou, S., McGee, L., Lau, D., Flannery, J.G., Miller, S.S., Wang, F., and Di Polo, A. (2002). Use of Recombinant Gene Delivery Vectors for Treating or Preventing Diseases of the Eye. (US20020194630), U.S. Patent."},{"key":"ref_187","unstructured":"Murray, J.C., and Semina, E. (2001). Methods and Compositions for the Diagnosis and Treatment of Cataracts. (US6306586), U.S. Patent."},{"key":"ref_188","unstructured":"Feinstein, E., and Skaliter, R. (2011). Inhibitors of RTP801 and Their Use in Disease Treatment. (US20110098337), U.S. Patent."},{"key":"ref_189","unstructured":"Jorgensen, J. (2008). Treatment of Retinopathies Using Gfra3 Agonists. (US20080260702), U.S. Patent."},{"key":"ref_190","unstructured":"McDaniel, D. (2006). System and Method for Photodynamic Cell Therapy. (US20060265030), U.S. Patent."},{"key":"ref_191","unstructured":"Yanni, J., Gamache, D.A., and Miller, S.T. (2006). Treatment of Dry Eye Restoring 15-Lipoxygenase Activity to Ocular Surface Cells. (US20060217325), U.S. Patent."},{"key":"ref_192","unstructured":"Walter, M.A., Jordan, T., and Raymond, V. (2003). Novel Mutations in the Freac3 Gene for Diagnosis and Prognosis of Glaucoma and Anterior Segment Dysgenesis. (US20030013087), U.S. Patent."},{"key":"ref_193","unstructured":"DeHazya, P., and Chen, W. (2003). Gene Therapy for Dry Eye Syndrome. (US20030087850), U.S. Patent."},{"key":"ref_194","unstructured":"Flannery, J., and Hauswirth, W.W. (2003). Expression of Glial-Derived Neurotrophic Factor for Treatment of Diseases of the Eye. (US20030129164), U.S. Patent."},{"key":"ref_195","unstructured":"Heller, R., Jaroszeski, M.J., Gilbert, R.A., and Hauswirth, W.H. (2006). Electroporation Device and Method for Delivery to Ocular Tissue. (WO20050277868), WO Patent."},{"key":"ref_196","unstructured":"Vargeese, C., Wang, W., Chen, T., Sweedler, D., and Haeberli, P. (2003). Polycationic Compositions for Cellular Delivery of Polynucleotides. (EP0941122B), EP Patent."},{"key":"ref_197","unstructured":"Chalberg, T.W., Blumenkranz, M., Palanker, D.V., Vankov, A., Huie, P., Marmor, M.F., and Calos, M.P. (2007). Ocular Gene Therapy Using Avalanche-Mediated Transfection. (US20070059835), U.S. Patent."},{"key":"ref_198","unstructured":"McDaniel, D.H. (2010). System and Method for Photodynamic Cell Therapy. (US20100081185A1), U.S. Patent."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/hum.2016.040","article-title":"Advances in Gene Therapy for Diseases of the Eye","volume":"27","author":"Petit","year":"2016","journal-title":"Hum. Gene. Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/eye.2017.158","article-title":"Technique of retinal gene therapy: Delivery of viral vector into the subretinal space","volume":"31","author":"Xue","year":"2017","journal-title":"Eye"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijpharm.2016.07.055","article-title":"In vitro, ex vivo and in vivo characterization of PLGA nanoparticles loading pranoprofen for ocular administration","volume":"511","author":"Canadas","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejpb.2015.01.026","article-title":"Biopharmaceutical profile of pranoprofen-loaded PLGA nanoparticles containing hydrogels for ocular administration","volume":"95","author":"Abrego","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.colsurfb.2014.09.042","article-title":"Physicochemical characterization of epigallocatechin gallate lipid nanoparticles (EGCG-LNs) for ocular instillation","volume":"123","author":"Fangueiro","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.nano.2011.10.015","article-title":"Release profile and transscleral permeation of triamcinolone acetonide loaded nanostructured lipid carriers (TA-NLC): In vitro and ex vivo studies","volume":"8","author":"Araujo","year":"2012","journal-title":"Nanomedicine"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/jps.22784","article-title":"Improved and safe transcorneal delivery of flurbiprofen by NLC and NLC-based hydrogels","volume":"101","author":"Nikolic","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ejpb.2016.08.001","article-title":"Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation","volume":"108","author":"Doktorovova","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/11\/9\/460\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:17:32Z","timestamp":1760188652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/11\/9\/460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":206,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["pharmaceutics11090460"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics11090460","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]}}}